DXS International plc Statement Re Impact Of Covid-19

 
TIDMDXSP 
 
 
   DXS INTERNATIONAL PLC 
 
   Update on Impact of Covid-19 
 
   DXS International plc ("DXS", the "Company"), the digital clinical 
decision support company, is pleased to provide shareholders with the 
following update on measures taken by the Company in response to 
COVID-19  and confirms that during this unprecedented interruption to 
business, DXS is continuing to deliver support of its solutions to 
frontline primary care doctors and nurses. 
 
   Being an accredited NHS solutions provider, DXS has well-established 
business continuity and disaster recovery protocols in place. These were 
triggered during the early stages of the COVID-19 outbreak and at this 
point, 95% percent of our staff, both in the United Kingdom and South 
Africa are successfully working from home and the company remains fully 
operational. 
 
   On the customer-facing front, DXS has supported national efforts to 
combat the pandemic by launching a clinical decision support toolkit via 
our DXS Point of Care solution for COVID-19 treatment and information. 
This is being used by doctors and nurses in the diagnosis and treatment 
of the disease. 
 
   Further to this, the company has set in place a technical support 
process designed to help clinicians access our Clinical Decision Support 
solution while working from home. DXS is pleased to report minimal 
disruption to the essential health technology services we provide to our 
NHS customers, namely our Point of Care product. 
 
   The outbreak of COVID-19, and the disruption it has wrought to the 
health care sector in particular, has placed a sharp focus on the 
necessity for health authorities to strongly consider digital health 
solutions such as those provided by DXS Point of Care and in particular 
our new ExpertCare solution for the management of hypertension, which 
has been identified as a high risk factor for those patients contracting 
COVID19. 
 
   We expect that once the situation begins to normalise, our new solutions 
can play an important role in helping clinicians manage mounting chronic 
disease patient backlogs created by the focus on the current pandemic. 
We are utilising the current situation to implement development of our 
technology that previously was only targeted for later in the year which 
we believe should enable us to hit the ground running when things begin 
to normalise. 
 
   David Immelman, CEO of DSX International PLC commented: "Although it is 
clear that the current situation has impacted our anticipated revenue 
growth in the current financial year, we are on track to match our 
previous years revenue. We are fortunate to have a recurring revenue 
stream that has enabled the business to continue delivering our service 
with minimum disruption to staff. Some product launches, ExpertCare, 
MyVytalCare and CompleteCare have seen delays given the NHS's focus on 
COVID-19, and it is not possible to predict the point at which new 
growth will begin. However with cash in the bank and sound products we 
remain optimistic about the future growth of the business and will 
update the market as soon as possible once there is more clarity on the 
situation. 
 
   We are pleased to be able to help support primary care doctors and 
nurses with our DXS Point of Care solution for COVID-19 treatment and 
information. In the area of digital health, the market is moving very 
fast, not only around Covid19, but around bringing solutions for remote 
monitoring and the treatment of vulnerable and chronically ill 
patients." 
 
   The Directors of DXS International plc accept responsibility for this 
announcement 
 
   Contacts: 
 
 
 
 
David Immelman (Chief Executive)               01252 719800 
 DXS International plc                david@dxs-systems.com 
https://www.dxs-systems.co.uk 
 
 
 
 
 
 
Corporate Advisor 
City & Merchant Limited 
 David Papworth           020 7101 7676 
 
 
 
 
 
 
Corporate Broker 
Hybridan LLP 
 Claire Louise Noyce   020 3764 2341 
 
 
   Notes to Editors 
 
   About DXS: 
 
   DXS International plc presents up to date treatment guidelines and 
recommendations, from Clinical Commissioning Groups and other trusted 
NHS sources, to doctors, nurses and pharmacists in their workflow and 
during the patient consultation. This effective clinical decision 
support ultimately translates to improved healthcare outcomes delivered 
more cost effectively and which should significantly contribute towards 
the NHS achieving its projected efficiency savings.

(END) Dow Jones Newswires

April 27, 2020 02:00 ET (06:00 GMT)

DXS (AQSE:DXSP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024